BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rader C. Bispecific antibodies in cancer immunotherapy. Curr Opin Biotechnol 2020;65:9-16. [PMID: 31841859 DOI: 10.1016/j.copbio.2019.11.020] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 11.3] [Reference Citation Analysis]
Number Citing Articles
1 Liguori L, Polcaro G, Nigro A, Conti V, Sellitto C, Perri F, Ottaiano A, Cascella M, Zeppa P, Caputo A, Pepe S, Sabbatino F. Bispecific Antibodies: A Novel Approach for the Treatment of Solid Tumors. Pharmaceutics 2022;14:2442. [DOI: 10.3390/pharmaceutics14112442] [Reference Citation Analysis]
2 Cyr MG, Mhibik M, Qi J, Peng H, Chang J, Gaglione EM, Eik D, Herrick J, Venables T, Novick SJ, Courouble VV, Griffin PR, Wiestner A, Rader C. Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia. J Immunother Cancer 2022;10:e004850. [DOI: 10.1136/jitc-2022-004850] [Reference Citation Analysis]
3 Zafarani A, Taghavi-Farahabadi M, Razizadeh MH, Amirzargar MR, Mansouri M, Mahmoudi M. The Role of NK Cells and Their Exosomes in Graft Versus Host Disease and Graft Versus Leukemia. Stem Cell Rev Rep 2022. [PMID: 35994137 DOI: 10.1007/s12015-022-10449-2] [Reference Citation Analysis]
4 Liu Y, Ao K, Bao F, Cheng Y, Hao Y, Zhang H, Fu S, Xu J, Wu Q. Development of a Bispecific Nanobody Targeting CD20 on B-Cell Lymphoma Cells and CD3 on T Cells. Vaccines 2022;10:1335. [DOI: 10.3390/vaccines10081335] [Reference Citation Analysis]
5 Sun W, Wang X, Wang D, Lu L, Lin H, Zhang Z, Jia Y, Nie X, Liu T, Fu W. CD40×HER2 bispecific antibody overcomes the CCL2-induced trastuzumab resistance in HER2-positive gastric cancer. J Immunother Cancer 2022;10:e005063. [PMID: 35851310 DOI: 10.1136/jitc-2022-005063] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Luo C, Wang P, He S, Zhu J, Shi Y, Wang J. Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer. Front Oncol 2022;12:919072. [DOI: 10.3389/fonc.2022.919072] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
7 Lv M, Liu Y, Liu W, Xing Y, Zhang S. Immunotherapy for Pediatric Acute Lymphoblastic Leukemia: Recent Advances and Future Perspectives. Front Immunol 2022;13:921894. [DOI: 10.3389/fimmu.2022.921894] [Reference Citation Analysis]
8 Ordóñez-Reyes C, Garcia-Robledo JE, Chamorro DF, Mosquera A, Sussmann L, Ruiz-Patiño A, Arrieta O, Zatarain-Barrón L, Rojas L, Russo A, de Miguel-Perez D, Rolfo C, Cardona AF. Bispecific Antibodies in Cancer Immunotherapy: A Novel Response to an Old Question. Pharmaceutics 2022;14:1243. [PMID: 35745815 DOI: 10.3390/pharmaceutics14061243] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Zhang R, Zhong L, Liu X, Liu X, Chen Q, Wu P, He J, Li Y, Zhao Y, Liu Z, Zu Y, Huang Y, Wang B. Microfluidic PLGA microcapsules with PD-L1 aptamers and docetaxel encapsulation for enhancing tumor immunity. Applied Materials Today 2022;27:101484. [DOI: 10.1016/j.apmt.2022.101484] [Reference Citation Analysis]
10 Xu T, Zhang J, Wang T, Wang X. Recombinant antibodies aggregation and overcoming strategies in CHO cells. Appl Microbiol Biotechnol 2022. [PMID: 35608667 DOI: 10.1007/s00253-022-11977-0] [Reference Citation Analysis]
11 Harwardt J, Bogen JP, Carrara SC, Ulitzka M, Grzeschik J, Hock B, Kolmar H. A Generic Strategy to Generate Bifunctional Two-in-One Antibodies by Chicken Immunization. Front Immunol 2022;13:888838. [DOI: 10.3389/fimmu.2022.888838] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Xu X, Gu H, Li H, Gao S, Shi X, Shen J, Li B, Wang H, Zheng K, Shao Z, Cheng P, Cha Z, Peng S, Nie Y, Li Z, Guo S, Qian B, Jin G. Large-cohort humanized NPI mice reconstituted with CD34+ hematopoietic stem cells are feasible for evaluating preclinical cancer immunotherapy. FASEB J 2022;36:e22244. [PMID: 35262964 DOI: 10.1096/fj.202101548RR] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Berois N, Pittini A, Osinaga E. Targeting Tumor Glycans for Cancer Therapy: Successes, Limitations, and Perspectives. Cancers (Basel) 2022;14:645. [PMID: 35158915 DOI: 10.3390/cancers14030645] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
14 Popovic LS, Brko GM, Popovic M. Immunotherapy of Lymphoma. Handbook of Cancer and Immunology 2022. [DOI: 10.1007/978-3-030-80962-1_229-1] [Reference Citation Analysis]
15 Ruirui Z, He J, Xu X, Li S, Peng H, Deng Z, Huang Y. PLGA-based drug delivery system for combined therapy of cancer: research progress. Mater Res Express 2021;8:122002. [DOI: 10.1088/2053-1591/ac3f5e] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
16 Wu Y, Yi M, Zhu S, Wang H, Wu K. Recent advances and challenges of bispecific antibodies in solid tumors. Exp Hematol Oncol 2021;10:56. [PMID: 34922633 DOI: 10.1186/s40164-021-00250-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
17 Castaneda-Puglianini O, Chavez JC. Bispecific antibodies for non-Hodgkin's lymphomas and multiple myeloma. Drugs Context 2021;10:2021-2-4. [PMID: 34603459 DOI: 10.7573/dic.2021-2-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
18 Abramson HN. Immunotherapy of Multiple Myeloma: Promise and Challenges. Immunotargets Ther 2021;10:343-71. [PMID: 34527606 DOI: 10.2147/ITT.S306103] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Ma H, Wang H, Sové RJ, Wang J, Giragossian C, Popel AS. Combination therapy with T cell engager and PD-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model. J Immunother Cancer 2020;8:e001141. [PMID: 32859743 DOI: 10.1136/jitc-2020-001141] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 18.0] [Reference Citation Analysis]
20 Gil-Garcia M, Ventura S. Multifunctional antibody-conjugated coiled-coil protein nanoparticles for selective cell targeting. Acta Biomater 2021;131:472-82. [PMID: 34192568 DOI: 10.1016/j.actbio.2021.06.040] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
21 Stoltzfus CR, Sivakumar R, Kunz L, Olin Pope BE, Menietti E, Speziale D, Adelfio R, Bacac M, Colombetti S, Perro M, Gerner MY. Multi-Parameter Quantitative Imaging of Tumor Microenvironments Reveals Perivascular Immune Niches Associated With Anti-Tumor Immunity. Front Immunol 2021;12:726492. [PMID: 34421928 DOI: 10.3389/fimmu.2021.726492] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
22 Stoltzfus CR, Sivakumar R, Kunz L, Pope BO, Menietti E, Speziale D, Adelfio R, Bacac M, Colombetti S, Perro M, Gerner MY. Multi-Parameter Quantitative Imaging of Tumor Microenvironments Reveals Perivascular Immune Niches Associated with Anti-Tumor Immunity.. [DOI: 10.1101/2021.06.17.448881] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Koelzer V, Herzig P, Zlobec I, Heinzelmann V, Lardinois D, Walseng E, Rader C, Mertz K, Zippelius A, Thommen D. Integrated functional and spatial profiling of tumour immune responses induced by immunotherapy: the iPROFILER platform. Immuno-Oncology and Technology 2021;10:100034. [DOI: 10.1016/j.iotech.2021.100034] [Reference Citation Analysis]
24 Goydel RS, Rader C. Antibody-based cancer therapy. Oncogene 2021;40:3655-64. [PMID: 33947958 DOI: 10.1038/s41388-021-01811-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 13.0] [Reference Citation Analysis]
25 Schwerdtfeger M, Benmebarek MR, Endres S, Subklewe M, Desiderio V, Kobold S. Chimeric Antigen Receptor-Modified T Cells and T Cell-Engaging Bispecific Antibodies: Different Tools for the Same Job. Curr Hematol Malig Rep 2021;16:218-33. [PMID: 33939108 DOI: 10.1007/s11899-021-00628-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Perez-Santos M, Anaya-Ruiz M, Sanchez-Esgua G, Villafaña-Diaz L, Barron-Villaverde D. Treatment of solid tumors using bispecific anti-PDL-1/ICOS antibody. Pharm Pat Anal 2021;10:67-72. [PMID: 33829869 DOI: 10.4155/ppa-2020-0035] [Reference Citation Analysis]
27 Rasche L, Hudecek M, Einsele H. What is the future of immunotherapy in multiple myeloma? Blood 2020;136:2491-7. [PMID: 32735639 DOI: 10.1182/blood.2019004176] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
28 Shou X, Liu Y, Wu D, Zhang H, Zhao Y, Sun W, Shen X. Black phosphorus quantum dots doped multifunctional hydrogel particles for cancer immunotherapy. Chemical Engineering Journal 2021;408:127349. [DOI: 10.1016/j.cej.2020.127349] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 16.0] [Reference Citation Analysis]
29 Arenas EJ, Martínez-Sabadell A, Rius Ruiz I, Román Alonso M, Escorihuela M, Luque A, Fajardo CA, Gros A, Klein C, Arribas J. Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation. Nat Commun 2021;12:1237. [PMID: 33623012 DOI: 10.1038/s41467-021-21445-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 15.0] [Reference Citation Analysis]
30 Valentinuzzi D, Jeraj R. Computational modelling of modern cancer immunotherapy. Phys Med Biol 2020;65:24TR01. [PMID: 33091898 DOI: 10.1088/1361-6560/abc3fc] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
31 Bogen JP, Carrara SC, Fiebig D, Grzeschik J, Hock B, Kolmar H. Expeditious Generation of Biparatopic Common Light Chain Antibodies via Chicken Immunization and Yeast Display Screening. Front Immunol 2020;11:606878. [PMID: 33424853 DOI: 10.3389/fimmu.2020.606878] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
32 Cheng Y, Zheng X, Wang X, Chen Y, Wei H, Sun R, Tian Z, Sun H. Trispecific killer engager 161519 enhances natural killer cell function and provides anti-tumor activity against CD19-positive cancers. Cancer Biol Med 2020;17:1026-38. [PMID: 33299651 DOI: 10.20892/j.issn.2095-3941.2020.0399] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
33 Yao HP, Tong XM, Wang MH. Pharmaceutical strategies in the emerging era of antibody-based biotherapeutics for the treatment of cancers overexpressing MET receptor tyrosine kinase. Drug Discov Today 2021;26:106-21. [PMID: 33171292 DOI: 10.1016/j.drudis.2020.11.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
34 Qi J, Rader C. Redirecting cytotoxic T cells with chemically programmed antibodies. Bioorg Med Chem 2020;28:115834. [PMID: 33166926 DOI: 10.1016/j.bmc.2020.115834] [Reference Citation Analysis]
35 Ma L, Gai J, Qiao P, Li Y, Li X, Zhu M, Li G, Wan Y. A novel bispecific nanobody with PD-L1/TIGIT dual immune checkpoint blockade. Biochemical and Biophysical Research Communications 2020;531:144-51. [DOI: 10.1016/j.bbrc.2020.07.072] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
36 Bockamp E, Rosigkeit S, Siegl D, Schuppan D. Nano-Enhanced Cancer Immunotherapy: Immunology Encounters Nanotechnology. Cells 2020;9:E2102. [PMID: 32942725 DOI: 10.3390/cells9092102] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
37 Blanco B, Ramírez-Fernández Á, Alvarez-Vallina L. Engineering Immune Cells for in vivo Secretion of Tumor-Specific T Cell-Redirecting Bispecific Antibodies. Front Immunol 2020;11:1792. [PMID: 32903593 DOI: 10.3389/fimmu.2020.01792] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]